nurse preparing an IV bag for an at-home patient.
Aging, Alternative Treatments, Athletic Performance, Beauty, Energy Boost, Headaches, Immune Boost, Instant Delivery, IV Hydration, IV Therapy, Ketamine IV Therapy

Esketamine vs. Racemic Ketamine: Which One is Right for You?

02/11/2026 | by

Ketamine has moved far beyond its origins as a surgical anesthetic. Today, it’s one of the most talked-about treatments in mental health, especially for people living with treatment-resistant depression (TRD) and severe depressive symptoms. Patients often hear two terms—esketamine (Spravato) and racemic ketamine—and wonder what the real difference is, and which option may be right for them. While both come from the same parent molecule, they’re not identical in how they work, how they’re regulated, or how they’re delivered.

This guide breaks down the science, the clinical differences, and what patients should consider when exploring ketamine-based therapies.

Understanding the Ketamine Molecule

The Enantiomer Concept

Ketamine is a chiral molecule, meaning it exists in two mirror-image forms called enantiomers: S-ketamine (esketamine) and R-ketamine. Think of these like left and right hands—similar in structure, but not identical in how they interact with the body. This concept of chirality is fundamental in pharmacology because enantiomers can have different strengths and side-effect profiles, even when derived from the same drug.

Molecular “Fit” and NMDA Receptors

Ketamine’s antidepressant effects are believed to stem largely from its interaction with NMDA receptors, a type of glutamate receptor in the brain involved in learning, memory, and mood regulation. Esketamine (the S-enantiomer) binds more strongly to NMDA receptors than R-ketamine, which is why lower doses of esketamine may achieve similar receptor activity compared to racemic ketamine. [1]

By modulating NMDA activity, ketamine triggers downstream effects that promote neuroplasticity, helping the brain form new connections that may support recovery from depression.

Historical Context: From Anesthesia to Neuroplasticity

Ketamine was first approved by the FDA in 1970 as a general anesthetic for humans, where it remains in use today, especially in emergency and surgical settings. Over time, clinicians observed that some patients experienced rapid improvements in mood after receiving ketamine during anesthesia. This observation led to decades of research into ketamine’s antidepressant properties, culminating in the development of esketamine as a targeted treatment for depression.

What Is Esketamine (Spravato)?

FDA Approval for TRD and Suicidal Ideation

Esketamine is marketed under the brand name Spravato and is FDA-approved for adults with treatment-resistant depression (TRD) and for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior. This makes esketamine the only ketamine-based therapy officially cleared by the FDA for depression.

The “S(+)” Advantage

Because esketamine is the S-enantiomer, it has a higher affinity for NMDA receptors than R-ketamine, meaning it can exert its effects at lower doses compared to the racemic mixture. [2] This receptor affinity is one reason esketamine was selected for large-scale clinical trials.

Clinical Protocol and REMS

Esketamine is administered as a nasal spray in a medical setting under a strict Risk Evaluation and Mitigation Strategy (REMS) program. Patients must be monitored for at least two hours after dosing due to potential side effects such as dissociation, sedation, and transient increases in blood pressure.

Target Audience

Spravato is intended for patients who have not responded adequately to at least two different oral antidepressants, a standard definition of treatment-resistant depression. [3]

What Is Racemic Ketamine?

The 50/50 Blend

Racemic ketamine contains equal parts S-ketamine and R-ketamine. This is the original formulation of ketamine that has been used in medicine for decades as an anesthetic. [4] 

Off-Label Use for Depression

While racemic ketamine is FDA-approved as an anesthetic, its use for depression is considered off-label. Off-label prescribing is legal and common in medicine when supported by clinical evidence, as explained by the FDA. Multiple clinical studies and reviews report rapid antidepressant effects in patients receiving IV ketamine for depression. [5]

Broader Interaction and the Role of R-Ketamine

Some preclinical research suggests that R-ketamine may produce longer-lasting antidepressant effects with fewer dissociative side effects than S-ketamine alone, though most of this evidence comes from animal and early-phase human studies. [6] This broader molecular profile is one reason some clinicians favor racemic ketamine in practice.

Versatility of Administration

Racemic ketamine can be administered via IV infusion, IM injection, or compounded nasal sprays, offering flexibility in dosing and treatment protocols. IV infusion is the most studied route in depression research. [7]

Esketamine vs. Racemic Ketamine: Key Differences at a Glance

  • Regulation: Esketamine is FDA-approved for depression; racemic ketamine is used off-label.
  • Molecular Profile: Esketamine contains only S-ketamine; racemic ketamine contains both S- and R-ketamine.
  • Delivery: Esketamine is nasal spray under REMS; racemic ketamine is often IV or IM.
  • Access & Insurance: Esketamine is more likely to be covered by insurance due to FDA approval, while racemic ketamine is typically self-pay.
  • Patient Experience: Some patients report racemic ketamine feels “smoother,” though experiences vary widely.

Frequently Asked Questions

Is One Version “Stronger” Than the Other?
Esketamine is more potent at the NMDA receptor, but racemic ketamine provides a broader molecular profile that may lead to different therapeutic effects.
Can I Switch From One to the Other?
Yes. Under clinical supervision, patients may switch based on response, tolerability, and access.
Why is Esketamine the Only FDA-approved Option for Depression?
This is largely due to the pharmaceutical development and patent process, as well as large-scale clinical trials conducted specifically for the Spravato brand.
Are the Side Effects Different?
Both can cause dissociation and temporary increases in blood pressure. Some patients report racemic ketamine feels subjectively “smoother,” but this varies person to person.

Explore ketamine-based therapy

If you’re exploring ketamine-based therapy for depression, the best next step is a personalized consultation with a qualified provider. Learn more about your treatment options and schedule an evaluation.

References

[1] National Library of Medicine, Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis, Bahji, A., Vazquez, G.H., Zarate Jr., C.A., 

January, 2022

[2] National LIbrary of Medicine, Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms, Kawczak, P., Feszak, I., Baczek, T.,  October 2024

[3] Cleveland Clinic, Ketamine Therapy, January 2026

[4] WebMD, Ketamine for Depression: What to Know, Bhandarai, S., MD, January 2025

[5] Verywell Health, The Surprising Role of Ketamine in Treating Depression: A Pharmacist’s Insight, Nunn, M., PharmD, December 2025

[6] Medical News Today, Ketamine injections effective for treatment-resistant depression, trial finds, Beake, Jessica, Ph.D., July 2023   

[7] Healthline, What to Know About Ketamine Therapy for Depression, Washington, N., DO, MPH, November 2022

, ,